DOCSLIB.ORG

PPL Full Year 2019 Annual Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
PPL Full Year 2019 Annual Report Parkway Pantai Limited and its subsidiaries Directors’ statement Year ended 31 December 2019 Directors’ statement We are pleased to submit this annual report to the member of the Company together with the audited financial statements for the financial year ended 31 December 2019. In our opinion: (a) the financial statements set out on pages FS1 to FS145 are drawn up so as to give a true and fair view of the financial position of the Group and of the Company as at 31 December 2019 and the financial performance, changes in equity and cash flows of the Group for the year ended on that date in accordance with the provisions of the Singapore Companies Act, Chapter 50 and Singapore Financial Reporting Standards (International); and The Directors would like to draw your attention to note 40 of the financial statements. Given the ongoing regulatory investigations, any further adjustments or disclosures, if required, would be made in the financial statements of the Group as appropriate when the outcome is known. (b) at the date of this statement, there are reasonable grounds to believe that the Company will be able to pay its debts as and when they fall due. The Board of Directors has, on the date of this statement, authorised these financial statements for issue. Directors Directors who served during the financial year until the date of this statement are: Dr Kelvin Loh Chi-Keon (Executive Director, appointed on 1 July 2019 CEO and Managing Director, appointed on 1 January 2020) Dr Tan See Leng (Group CEO & Managing Director, resigned on 31 December 2019) Low Soon Teck Directors’ interests According to the register kept by the Company for the purposes of Section 164 of the Companies Act, Chapter 50 (“the Act”), particulars of interests of directors who held office at the end of the financial year (including those held by their spouses and children) in shares, debentures, warrants and share options in the Company and in related corporations (other than wholly-owned subsidiaries) are as follows: Holdings in the name Other holdings in which Name of director and corporation of the director, spouse the director is deemed in which interests are held or children to have an interest At beginning At beginning of the year/ of the year/ date of At end date of At end appointment of the year appointment of the year The Company Perpetual securities Dr Tan See Leng US$3,000,000 – – – 1 Parkway Pantai Limited and its subsidiaries Directors’ statement Year ended 31 December 2019 Holdings in the name Other holdings in which Name of director and corporation of the director, spouse the director is deemed in which interests are held or children to have an interest At beginning At beginning of the year/ of the year/ date of At end date of At end appointment of the year appointment of the year Ultimate holding company IHH Healthcare Berhad Ordinary shares of RM1 each Dr Tan See Leng 8,201,800 – – – Low Soon Teck 216,000 16,300 – – IHH Long Term Incentive Plan1 2017 Grant Dr Tan See Leng 426,000 – – – Low Soon Teck 73,000 – – – 2018 Grant Dr Tan See Leng 882,000 441,000 – – Low Soon Teck 146,000 73,000 – – 2019 Grant Dr Tan See Leng – 1,110,000 – – Low Soon Teck – 290,000 – – IHH Enterprise Option Scheme2 2015 Option Grant Dr Tan See Leng 3,998,000 3,998,000 – – 2016 Option Grant A Dr Tan See Leng 6,105,000 6,105,000 – – 2016 Option Grant B Dr Tan See Leng 4,126,000 4,126,000 – – Low Soon Teck 100,000 100,000 – – 2018 Option Grant Dr Tan See Leng 6,432,000 6,432,000 – – Low Soon Teck 2,016,000 2,016,000 – – 2019 Option Grant Dr Tan See Leng – 9,748,000 – – Low Soon Teck – 704,000 – – Subsidiary Parkway Life REIT Units in Real Estate Investment Trust Dr Kelvin Loh Chi-Keon 120,000 120,000 – – 1 The IHH Healthcare Berhad (“IHHHB”) Long Term Incentive Plan (“IHH LTIP”) was established on 25 March 2011. Under the IHH LTIP Bye Laws (“Bye Laws”), eligible employees may be granted LTIP units which will vest over a three-year period in equal proportions each year. Each unit of the LTIP is entitled to be converted to one ordinary share of IHHHB. 2 The Options were granted under IHHHB’s Enterprise Option Scheme as set out in the Directors’ Statement of IHHHB for the year ended 31 December 2019. Subject to the terms of the Enterprise Option Scheme Bye Laws (as the same may from time to time be amended), the Options will vest in the participants over a three-year period in equal proportions (or substantially equal proportion) each year. 2 Parkway Pantai Limited and its subsidiaries Financial statements Year ended 31 December 2019 Statements of financial position As at 31 December 2019 Group Company Note 2019 2018 2019 2018 $’000 $’000 $’000 $’000 Restated* Assets Property, plant and equipment 4 2,872,593 3,538,820 1 4 Right-of-use assets 5 1,714,865 – – – Prepaid lease payments 6 – 334,758 – – Investment properties 7 1,148,228 1,088,800 – – Intangible assets 8 1,344,385 1,118,825 – – Interests in subsidiaries 9 – – 7,337,586 7,170,319 Interests in associates 10 30,260 287,891 – – Interests in joint ventures 11 69,561 67,965 – – Other financial assets 12 15,305 6,140 – – Trade and other receivables 16 40,957 32,433 – – Financial derivatives 23 3,018 237 – – Deferred tax assets 13 101,172 106,288 – – Tax recoverables 126,178 90,913 – – Non-current assets 7,466,522 6,673,070 7,337,587 7,170,323 Development properties 14 27,563 26,552 – – Inventories 15 73,709 68,257 – – Other financial assets 12 43,021 33,962 – – Trade and other receivables 16 496,538 461,390 9,675 359,432 Financial derivatives 23 28 1,279 – – Tax recoverables 1,333 2,782 – – Cash and cash equivalents 17 1,446,811 2,099,852 111,676 33,717 2,089,003 2,694,074 121,351 393,149 Assets held for sale 18 2,209 2,121 – – Current assets 2,091,212 2,696,195 121,351 393,149 Total assets 9,557,734 9,369,265 7,458,938 7,563,472 The accompanying notes form an integral part of these financial statements. FS1 Parkway Pantai Limited and its subsidiaries Financial statements Year ended 31 December 2019 Statements of financial position (cont’d) As at 31 December 2019 Group Company Note 2019 2018 2019 2018 $’000 $’000 $’000 $’000 Restated* Equity Share capital 19 5,950,860 5,120,860 5,950,860 5,120,860 Other reserves 20 (3,107,053) (3,121,306) (172) (287) Retained earnings 1,038,645 870,532 413,713 409,519 Equity attributable to owner of the Company 3,882,452 2,870,086 6,364,401 5,530,092 Perpetual securities 21 690,770 690,788 690,770 690,788 Non-controlling interests 38 942,083 1,165,921 – – Total equity 5,515,305 4,726,795 7,055,171 6,220,880 Liabilities Loans and borrowings 22 2,043,480 2,174,938 326,925 492,125 Lease liabilities 5 311,404 – – – Financial derivatives 23 817 4,002 – – Employee benefits 24 26,430 26,948 – – Trade and other payables 25 30,402 143,761 – – Deferred tax liabilities 13 188,460 139,967 22 – Non-current liabilities 2,600,993 2,489,616 326,947 492,125 Bank overdrafts 17 39,870 26,712 – – Loans and borrowings 22 160,778 122,221 – 18,000 Lease liabilities 5 42,092 – – – Financial derivatives 23 2,496 1,951 – – Employee benefits 24 43,220 38,942 – – Trade and other payables 25 1,041,347 1,838,662 75,996 831,310 Current tax payable 111,633 124,366 824 1,157 Current liabilities 1,441,436 2,152,854 76,820 850,467 Total liabilities 4,042,429 4,642,470 403,767 1,342,592 Total equity and liabilities 9,557,734 9,369,265 7,458,938 7,563,472 * Refer to notes 42 and 43. The Group initially applied SFRS(I) 16 Leases at 1 January 2019, using the modified retrospective approach. Under this approach, comparative information is not restated and the cumulative effect of initially applying SFRS(I) 16, if any, is recognised in retained earnings at the date of initial application. The comparative information is restated on account of adjustments to provisional fair values for acquisition of Fortis Healthcare Limited (“Fortis”) on completion of purchase price allocation during the year. The accompanying notes form an integral part of these financial statements. FS2 Parkway Pantai Limited and its subsidiaries Financial statements Year ended 31 December 2019 Consolidated statement of comprehensive income Year ended 31 December 2019 Group Note 2019 2018 $’000 $’000 Revenue 26 3,588,092 2,539,559 Other operating income 83,352 107,960 Inventories and consumables (706,652) (480,316) Purchased and contracted services (457,214) (252,225) Development cost of properties sold (243) – Depreciation and impairment of property, plant and equipment 4 (229,323) (202,829) Depreciation and impairment of right-of-use assets 5 (71,978) – Amortisation of prepaid lease payments 6 – (5,940) Amortisation of intangible assets 8 (13,821) (5,057) Staff costs 27 (1,155,565) (899,790) Operating lease expenses 5 (16,369) (51,331) Allowance for impairment loss (made)/written back on trade and other receivables (19,688) 13,505 Other operating expenses (575,857) (363,430) Finance income 27 35,363 37,130 Finance costs 27 (114,791) (54,007) Share of profits of associates (net of tax) 10 21,173 3,855 Share of profits of joint ventures (net of tax) 11 3,250 635 Profit before tax 27 369,729 387,719 Tax expense 28 (164,371) (98,744) Profit for the year 205,358 288,975 Other comprehensive income Items that will not be reclassified to profit or loss: Defined benefit plan remeasurements 24 626 (409) Change in fair value of equity investments at FVOCI (3,049) – Tax on other comprehensive income and effect of change in tax rate 13 (990) 140 (3,413) (269) Items that are or may be reclassified subsequently to profit or loss: Foreign currency translation differences of foreign operations (restated) (59,845) (2,599) Net gain/(loss) on hedge of net investments in foreign operations 486 (26,291) Net movement for cash flow hedges 323 1,423 Net movement in cost of hedging reserve 301 – (58,735) (27,467) Other comprehensive income for the year, net of tax (restated) (62,148) (27,736) Total comprehensive income for the year (restated) 143,210 261,239 The accompanying notes form an integral part of these financial statements.
Load more

Recommended publications
  • Quest for Quality the 2018 IHH Quality Summit Promotes Excellent Healthcare Through Effective Partnerships
    mosaic OCT - DEC 2018 OCT DEC mosaic 2018 REGION’S FIRST HEART WORK EMERGENCY-READY Breaking ground for Raising awareness of It’s about saving lives Proton Beam Therapy Centre cardiovascular disease Quest For Quality The 2018 IHH Quality Summit promotes excellent healthcare through effective partnerships Celebrating our nurses, the bright sparks in humanity! A Parkway Pantai Publication EDITOR’S NOTE SUSTAINING A QUALITY CULTURE Some say that the mark of true quality is the quest for continuous improvement. For Parkway Pantai, that means constantly refining and enhancing the healthcare experience we provide our patients. cross the numerous geographies in which we operate, we endeavour to give our patients access to the best care and expertise available. Echoing that ideal in this issue, we recap the highlights of the IHH Quality Summit in AKuala Lumpur, where quality improvements and achievements by our teams are recognised and celebrated (Page 8). To advance clinical excellence and services, we unveiled our plans to launch the region’s first Proton Beam Therapy Centre at Mount Elizabeth Novena Hospital in 2021 (Page 14). Our Malaysia Operations Division also introduced new equipment and tests to benefit patients across the peninsula (Page 16). We continue to deliver on our mission to make a difference in people’s lives. In a show of support for academia and education, a new S$2 million Mount Elizabeth-Gleneagles Graduate Scholarship Fund with Duke-NUS Medical School was recently established (Page 20). Through our Life Renewed programme in Singapore and Malaysia, we continue to bring hope to the less fortunate by providing free medical treatment in our hospitals (Page 22 & 24).
    [Show full text]
  • Enhancing the Competitiveness of the Health Services Sector in Singapore
    CHAPTER 3 Transforming the ASEAN Economic Community (AEC) into a Global Services Hub: Enhancing the Competitiveness of the Health Services Sector in Singapore KAI HONG PHUA Lee Kuan Yew School of Public Policy, National University of Singapore NICOLA S POCOCK Lee Kuan Yew School of Public Policy, National University of Singapore 1. Introduction Singapore was the first country in the region to officially articulate an aim to attract medical tourists and promote the export of health services overseas. In 2003, the Healthcare Services Working Group (HSWG) of the Economic Review Committee recommended that Singapore attract one million foreign patients by 2012. To achieve this goal, the Singapore Tourism Board (STB), along with the Economic Development Board (EDB) and International Enterprise (IE) Singapore, launched SingaporeMedicine in 2003, a multi-agency initiative that aims to promote, develop and maintain Singapore as an international medical hub. However, in recent years, the push for medical tourism has been muted. Sectiononeof this paper summarizes the Singapore context for a past medical tourism hub policy, followed by an overview of the health system, with policy implications for the system should medical tourism become a major growth area. Methodology is then described in section two, followed by the findings of the SWOT analysis conducted among stakeholders in the health services sector. 111 The objective of this paper is to: 1. Undertake a SWOT analysis for the health services sector in Singapore. 2. Undertake an analysis of policies/regulatory/institutional support for the health services sector in Singapore. 3. Develop a profiling of firms which are considered key players for the health services industry.
    [Show full text]
  • Industrial Sponsorships
    Introduction to Industrial Sponsorships Candidates who have the passion to become healthcare professionals and would like to seek financial sponsorship in the healthcare sector may approach the following organisations to discuss their interest in joining the sector. Please note that any sponsorship awarded may typically come with obligations to serve a working bond with the sponsoring organisation. Parkway Pantai Student Scholarship [Radiology] Parkway Pantai is one of Asia’s largest integrated private healthcare groups operating in Singapore, Malaysia, India, China, Brunei and United Arab Emirates. For over 40 years, its Mount Elizabeth, Gleneagles, Pantai and Parkway brands have established themselves as the region’s best known brands in private healthcare, synonymous with best-in-class patient experience and outcomes. It is part of IHH Healthcare, the world’s second largest healthcare group by market capitalisation. IHH operates more than 10,000 licensed beds across 50 hospitals in 10 countries worldwide. In Singapore, Parkway Pantai is the largest private healthcare operator with four JCI- accredited, multi-specialty tertiary hospitals - Mount Elizabeth Hospital, Mount Elizabeth Novena Hospital, Gleneagles Hospital and Parkway East Hospital. It also owns Parkway Shenton, a large network of primary healthcare clinics and services, ParkwayHealth Radiology, ParkwayHealth Laboratory and Parkway College. Types of Sponsorships: Partial / Full Sponsorships Bond Duration: 3 years upon graduation / 6 years upon graduation Contact Person: Linus Leow Email Address: [email protected] Website: https://www.parkwayhospitals.com/ Industrial Sponsorships by other Healthcare Institutions The following organisations have also sponsored candidates in the past and may offer sponsorships for accepted candidates of this programme. You may wish to visit the organisations’ websites for more details or contact the relevant person in the respective organisation by phone or in writing to find out the selection procedures.
    [Show full text]
  • Leading Change in Emerging Health Markets L
    Making Global Connections LeadingL Change in Emerging Health Markets GlobalGl private health care conference Speakers and Moderators Dr. Iain Barton Managing Director Imperial Health Sciences Imperial acquired the Health Sciences businesses of RTT in 2013. Iain Barton joined the group in 2000 as Strategic Director, before moving to the healthcare division as CEO in 2005. On assuming the Group CEO role in 2010, Iain led the unbundling of the specialized healthcare operations across Africa and their acquisition by Imperial in 2013. With ten years in medical practice and more than a decade in healthcare supply chain management, Iain’s unique skill set matches Imperial’s core values of international standard service and customer focus. In addition, Iain’s experience in Development Aid strategy and specifically his involvement in the planning and operations of the supply chain management system (SCMS) for the US Government’s PEPFAR initiative, provide a secure foundation for IHS’s African business development plans. Heading Africa’s leading healthcare supply chain partner, Iain’s professional standards and industry understanding are showing dividends in business growth, service integrity and client loyalty for Imperial. Jin-Yong Cai Executive Vice President and CEO International Finance Corporation Jin-Yong Cai is the Executive Vice President and CEO of IFC. Prior to accepting this appointment, Jin-Yong served as Participating Managing Director in Goldman Sachs Group and Chief Executive of Goldman Sachs Gao Hua. In this capacity, he has gathered a wealth of experience working with various financial products, and has a proven track record managing highly complex business transactions, demonstrating sound judgment on risk, and forging deep relationships with clients in both developed and developing markets across the globe.
    [Show full text]
  • Topping up Ceremony for Gleneagles Kota Kinabalu Hospital
    PRESS RELEASE FOR IMMEDIATE RELEASE Major Healthcare Provider Flexes Its Wings Topping Up Ceremony for Gleneagles Kota Kinabalu Hospital KOTA KINABALU, 8th APRIL - Gleneagles Hospitals, the brand synonymous with excellent private healthcare in the South East Asian region, will soon be available to the people of Sabah via its latest addition, Gleneagles Kota Kinabalu. The purpose built hospital, which will be opening its doors in the 1st Quarter of 2015, had its topping up ceremony yesterday, officiated by the Y.B. Datuk Seri Panglima Masidi Manjun, Minister of Tourism, Culture and Environment of Sabah. The topping up ceremony, held at the hospital’s construction site, was done to commemorate the overall completion of the building's structure by the developer. The ceremony was attended by Tan Sri Dato' Dr Abu Bakar bin Suleiman, the Chairman of IHH Healthcare Berhad, Dato’ Mohammed Azlan Bin Hashim, the Chairman of Parkway Pantai Limited, Datuk Khairil Anuar bin Abdullah, the Chairman of Pantai Holdings Berhad, Dr Tan See Leng, the Managing Director and Chief Executive Officer of IHH Healthcare Berhad and Group Chief Executive Officer and Managing Director of Parkway Pantai, Mr Alvin Lee Swee Hee, the Chief Executive Officer (Malaysia Operations), Pantai Holdings Berhad, Dato’ Amir Firdaus, Senior General Manager (Malaysia Operations), Pantai Holdings Berhad, the senior management teams and about 200 local representatives from both the government and the private sector. Dr Tan, when delivering his opening remark said that the topping up ceremony represented an important milestone for Parkway Pantai Limited and IHH Healthcare Berhad. Gleneagles Kota Kinabalu will be the first foray by the group in establishing a private healthcare facility in East Malaysia.
    [Show full text]
  • Q3-Mosaic 2018 Digital.Pdf
    JUL SEP mosaic 2018 SHARING RECOGNISING BEDBOUND KNOWLEDGE DISTINGUISHED SERVICE NO MORE Advancing healthcare Highlights from Long Service Continental Hospitals in Malaysia Awards in Singapore puts a patient on his feet Heart of Healthcare Celebrating our nurses, the bright sparks in humanity! A Parkway Pantai Publication EDITOR’S NOTE BEACONS OF HEALTHCARE Our nurses will bright up your day and bring on the smiles. his issue of Mosaic homes in on our nurses and their achievements and contributions as Parkway Pantai celebrates Nurses’ Day across its various markets (Page 10). We applaud all our nurses who serve Tat the frontlines and who continually inspire us with their altruism and passion. Our heartiest congratulations to Mona Soh, who is the first private sector nurse in Singapore to receive the prestigious President’s Award for Nurses (Page 14), and our four recipients of the Singapore Ministry of Health Nurses’ Merit Awards (Page 16). They exemplify the good work of our nursing workforce as they go about providing round-the-clock comfort and care to our patients. As a healthcare provider, people are central to our success. We catch up with three Long Service Award recipients from Singapore Operations Division (Page 34) and recognise the excellent job of a neurosurgeon in India who brought a patient in despair back from the brink (Page 38). Follow us on People, passion and pride – these are certainly worth mosaicparkwaypantai celebrating. Staff can also contribute stories on Mosaic Yammer. www.yammer.com/ parkwaypantai.com Lim Bee Ling 01 Contents JUL SEP 2018 20 04 14 OUR WORK OUR HIGHLIGHTS 20 THE BEST MINDS IN THE BUSINESS GLENEAGLES HONG 04 Chief Executive Officer KONG TURNS ONE of Singapore Operations Marking a successful first Division talks about year with a celebratory healthcare innovation on dinner.
    [Show full text]
  • IHH Healthcare Invests in Genomic Medicine Company to Provide Cancer Patients Better Treatment Outcomes
    FOR IMMEDIATE RELEASE Kuala Lumpur/ Singapore, 20 November 2019 IHH Healthcare Invests In Genomic Medicine Company to Provide Cancer Patients Better Treatment Outcomes • Led minority investment in genomic medicine start-up Lucence • Offers patients clinically validated blood-based cancer screening and treatment monitoring solutions with a focus on cancers commonly found in Asia • Embraces value-based healthcare approach that aims to improve clinical outcomes through less invasive, more precise, and more affordable technology IHH Healthcare (“IHH” or the “Group”), a leading premium global healthcare provider, led a minority investment in Singapore-based genomic medicine company Lucence as part of a USD $20 million Series A. The investment is part of IHH’s collaboration with start-ups to deploy innovative and cutting-edge healthcare technology to enhance the patient experience, treatment and clinical outcomes across its network of 80 hospitals in 10 countries. In Singapore, for example, IHH is working with a local start-up to improve estimated bill size for patients ahead of admission through predictive AI. The partnership with Lucence will give IHH patients access to Lucence’s suite of cancer diagnostics and AI- driven analytics. Lucence uses liquid biopsy, a blood-based technology that is less invasive than tissue biopsies, to help clinicians discover a range of information about a tumour and aid in their treatment decisions through a simple blood sample. It focuses on Asia-prevalent cancers such as lung, breast, colorectal, pancreatic, nasopharyngeal and liver cancers. Dr Kelvin Loh, Chief Executive Officer (Designate) of IHH Healthcare, said, “Liquid biopsy is a game- changer in our endeavour to provide cancer patients with better, value-driven outcomes through precise treatment selections and more affordable care.
    [Show full text]
  • Parkway Pantai Limited’S (“Parkway Pantai”) Acquisition Loan, and These Savings Contributed to PATMI
    IHH Healthcare Berhad Annual Report 2012 47 MANAGING DIRECTOR’S Review of Operations IHH Healthcare Berhad MANAGING dIRECTOR’S Annual Report 2012 REVIEW OF OPERATIONS 48 Dear Shareholders, I am pleased to report that despite a challenging global economic backdrop, IHH Healthcare Berhad (“IHH” or the “Group”) made strong strides forward and delivered robust performance across key financial and operational metrics in Financial Year 2012 (“FY 2012”). Our success is all the more satisfying given that this was our maiden year as a listed-entity. Managing Director Dr Lim Cheok Peng IHH Healthcare Berhad Annual Report 2012 49 IHH Healthcare Berhad MANAGING dIRECTOR’S REVIEW OF OPERATIONS Annual Report 2012 50 For the financial year ended 31 December 2012, the Group’s first full-year of results, we more than doubled our revenue as well as earnings before interest, tax, depreciation, amortisation, exchange differences and other non-operational items (“EBITDA”). Revenue rose 110% to RM7.0 billion year-on-year (“YoY”) and EBITDA by 109% to RM1.4 billion YoY. The Group’s rapid growth in FY 2012 was underpinned by three key factors, namely, consistent growth across all existing operations; the consolidation of Acibadem Holding (“Acibadem”) from 24 January 2012; and the one-time sale of 216 medical suites at the new Mount Elizabeth Novena Hospital and Specialist Centre in Singapore (“Mount Elizabeth Novena”). Stripping out the sale of medical suites, we still registered solid growth of 73% and 69% respectively with regard to our full-year revenue and EBITDA. Excluding exceptional items, our profit after tax and minority interests (“PATMI”) for FY 2012 rose 56% to RM686.6 million on the back of the strong EBITDA growth.
    [Show full text]
  • 110 Sengkang East Way Singapore 544886
    Pre-Registration Training Institutions (Oct 2018) Institution Address / Tel / Fax Pharmacy Manager 378 Alexandra Road Ms Hooi Pik Yee 1. Pharmacy Dept Singapore 159964 [email protected] Alexandra Hospital Tel : 63793322 Fax: 63793339 63706695 2 Simei Street 3 Ms Wong Hai Hong 2. Pharmacy Dept Singapore 529899 [email protected] Changi General Hospital Tel: 68501888 Fax: 67862485 68501881 3. Pharmacy Dept 10 Buangkok View Ms Soh Lay Beng Institute of Mental Health Singapore 539747 [email protected] Tel: 63892000 Fax: 63851050 63892073 4. Pharmacy Dept 100 Bukit Timah Road Ms Irene Quay K K Women’s & Children’s Hospital Singapore 229899 [email protected] Tel: 63942460 Fax: 63942465 63942346 90 Yishun Central Ms Supadhara Ramaiyah 5. Pharmacy Dept Singapore 768828 [email protected] Khoo Teck Puat Hospital Tel: 6602 2622 Fax: 66023688 66022622 3 Fusionopolis Link Ms Lim Li-Ching 6. National Healthcare Group #05-07 Nexus@one-north [email protected] Pharmacy Singapore 138543 63402313 Tel: 63402300 Fax: 63402301 7. Pharmacy Dept Pharmacy Level 3, 11 Hospital Drive Ms Chang Yok Ying National Cancer Centre Singapore Singapore 169610 [email protected] Tel: 64368138 Fax: 62202573 64368091 5 Hospital Drive Mr Teo Siew Chong 8. Pharmacy Dept Singapore 169609 [email protected] National Heart Centre Singapore Tel : 64367857 Fax: 64367846 64367858 5 Lower Kent Ridge Road Mr Wu Tuck Seng 9. Pharmacy Dept Singapore 119074 [email protected] National University Hospital Tel: 67725007 Fax: 68737121 67725008 1 Jurong East Street 21 Ms Kimmy Liew 10.
    [Show full text]
  • Parkway Hospitals Singapore Inks Healthcare Services Mou with Democratic Republic of Timor-Leste
    MEDIA RELEASE PARKWAY HOSPITALS SINGAPORE INKS HEALTHCARE SERVICES MOU WITH DEMOCRATIC REPUBLIC OF TIMOR-LESTE Singapore, 8 August 2019 – Parkway Hospitals Singapore (PHSPL) today inked a Memorandum of Understanding (MOU) with the Ministry of Health of the Democratic Republic of Timor-Leste (MOHTL) to facilitate patients requiring medical treatment abroad and the establishment of a representative office in Timor-Leste. The MOU also paves the way for clinical training opportunities and educational exchange programmes for doctors and healthcare professionals on both sides. Under the non-binding memorandum, MOHTL will refer its staff, Timor-Leste Members of Parliament and citizens of Timor-Leste for care and treatment in Singapore at PHSPL hospitals, which include Gleneagles, Mount Elizabeth (Orchard), Mount Elizabeth Novena and Parkway East hospitals. To this end, PHSPL will establish a Representative Office in Dili, Timor-Leste to facilitate an efficient patient management protocol. The Office will also serve as a single point of contact for better communications, information exchange and to support administrative and logistical arrangements. The MOU will also allow for greater exchange between healthcare professionals on both sides. Doctors and nurses may take part in health training or educational exchange opportunities in the form of medical seminars/ workshops and nursing observer-ship programmes. “Medical expertise at our hospitals in Singapore is highly trusted and sought after by patients across the region. We are known for world-class clinical excellence and superior treatment outcomes,” said Mr Phua Tien Beng, Chief Executive Officer, Singapore Operations Division, Parkway Pantai. “But this collaboration goes beyond just extending healthcare expertise to the people of Timor-Leste.
    [Show full text]
  • Ai and Robotics in Hospital and Healthcare Conference
    AI AND ROBOTICS IN HOSPITAL AND HEALTHCARE CONFERENCE Harnessing AI For Chronic Diseases, Hospital Management And Patient Care Pre-Conference Site Tour: 19 August 2020 Main Conference: 20 – 21 August 2020 Venue: Sheraton Towers, Singapore 5 POWERFUL REASONS TO ATTEND THE AI & ROBOTICS IN HOSPITALS AND HEALTHCARE CONFERENCE Discover The Latest Acquire New Skills And Learn How To Elevate The Innovations In AI And Robotics Strategies To Effectively Patient Experience With AI- That Can Boost Hospitals’ Incorporate AI And Robotics Powered Medical Devices Efficiency And Precision Into Healthcare Operations See How To Maximize The ROI Of Your Network And Build Valuable Partnerships With Investments In Hospital And Healthcare Innovative Minds At The Forefront Of Medical Digitization And Healthcare Technology HIGHLY ACCLAIMED SPEAKERS & KEY TOPICS INCLUDE 19 - 21 AUGUST 2020 | SHERATON TOWERS, SINGAPORE PROF ROBERT JT STEPHEN CHAN DINESH KUMAR MORRIS Clinical Director Department Senior Consultant, Director Chief Technology Strategist of Knowledge and of Spine Ministry of Health Innovation Changi General Hospital Transformation (MOHT) Woodlands Integrated Health Campus HARNESSING DATA SCIENCE AND PIONEERING THE FUTURE OF FIRST IN SOUTH-EAST ASIA: HOW AI TO IMPROVE MANAGEMENT OF PATIENT CARE WITH AI: A CASE SURGEONS USES ROBOTS FOR CHRONIC DISEASES AND MENTAL STUDY FROM WOODLANDS PRECISE HEART SURGERY HEALTH IN SINGAPORE HEALTH CAMPUS JONATHAN SCOLNICK DR. TAN YAN YUAN HONG CHOON OH Research Scientist Clinical Artificial Assistant Director National
    [Show full text]
  • Healthcare Provider Parkway Pantai Allocates 100 Staff and RM500,000 for Flood Relief Efforts
    PRESS RELEASE FOR IMMEDIATE RELEASE Healthcare Provider Parkway Pantai Allocates 100 Staff and RM500,000 for Flood Relief Efforts George Town, 9 November 2017 – Providing proper medical aid during times of disaster is crucial towards protecting the health and wellbeing of the public. As a key private healthcare provider in Malaysia, Parkway Pantai understands this well and is committed to ensure that medical assistance is made available to the people in Penang, Kedah and other areas affected by the flood. A team of 100 staff has been apportioned by Parkway Pantai to provide aftermath assistance to flood victims. The team consists of doctors, nurses and general staff from Parkway Pantai’s hospitals in the northern region – namely Gleneagles Penang, Pantai Hospital Penang and Pantai Hospital Sungai Petani – who are providing medical assistance and helping to clean homes affected by floodwaters. Medical assistance and help with cleaning Flood victims who are temporarily sheltered at the Bukit Mertajam district office have been attended by nurses and staff from the emergency department at Pantai Hospital Penang. Stroke patients and patients with minor injuries were assessed and provided with medical treatment by Parkway Pantai staff on the ground. In Sungai Petani, staff from Pantai Hospital Sungai Petani have been involved in cleaning up the houses of flood victims. The week-long effort will see more staff helping out in cleaning the houses of more than 100 families. The hospital will also work with the Sungai Petani Village Development and Security Committee to deploy any further aid required. Parkway Pantai is also working alongside Mercy Malaysia to ensure that the assistance provided is appropriate and coordinated.
    [Show full text]